SMMT Q3 2023 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$599,000

Operating Income

-$20M

Net Income

-$21M

EPS (Diluted)

$-0.03

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$577,860

Balance Sheet

Total Assets

$218M

Total Liabilities

$119M

Stockholders' Equity

$99M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$220,000	-100.0%
Gross Profit	-$599,000	$220,000	-372.3%
Operating Income	-$20M	-$17M	-21.0%
Net Income	-$21M	-$21M	+0.5%